Dear NORML Members and Supporters:
Please allow me to wax nostalgic for a moment or two about the wonderful progress we have all seen in recent years, with a majority of the country now supporting and end to prohibition, and the adoption of various forms of marijuana legalization in many states. The political environment was not always so favorable.
When we started NORML in 1970, only 12% of the population supported legalization; 88% supported prohibition. It has been a long, slow and sometimes arduous effort, but we have finally won the hearts and minds of most is our citizens, despite the fact that only 14% are marijuana smokers. They have concluded that prohibition causes far more harm to society than the use of marijuana, and that regulating the sale of marijuana is the better policy.
With our recent spate of victories at the state level, currently 17 states and the District of Columbia (and several major cities) have stopped treating marijuana smokers like criminals; 23 states and the District of Columbia offer legal medical marijuana; and four states have fully legalized marijuana with state-licensed dispensaries. We have reached a tipping point in the decades-long drive to legalize marijuana, and with your continued support, there is no turning back!
And we can already see the benefits: for the fourth year in a row the number of Americans arrested on marijuana charges has declined. And these declines will only increase as we move forward with victories in additional states. We expect full legalization voter initiatives to be approved in 2016 in California, Nevada, Massachusetts, and Maine (and perhaps a few others that are only now being organized).
NORML’s Work Has Just Begun
In each of these legalized states, the real job of NORML is just getting started. When I founded NORML it was the result of some work I had done with consumer-advocate Ralph Nader, and I envisioned the organization as a Consumers’ Union for marijuana smokers. As a consumer lobby, we must work to assure the smokers have access to legal marijuana that is safe, convenient and affordable. We must demand that the marijuana be tested to assure there are no molds or pesticides, and we need to know the strength of the THC and the CBD, and to know what terpenoids are present. These are basic consumer rights that we could not get when marijuana was only available on the black market, but which we have every right to expect in a legal market.
And to encourage the newly legal marijuana industry to abide by a set of “best practices”, we have established the NORML Business Network, to help consumers recognize “consumer-friendly” companies. As in any new industry, there are some whose only interest is to maximize their profits, but many of these new companies feel a responsibility to adopt higher standards. The NORML Business Network will help consumers distinguish between the two.
4 Down – 46 To Go!
We obviously have much work to be done before we totally end marijuana prohibition and stop the arrest of responsible marijuana smokers all across America. But we have made a substantial start, and the public support and political momentum is clearly on our side. With your continued support, we will see this fight through to a successful conclusion, and set a standard for the rest of the world to follow.
Please make a generous contribution to NORML today of $50 or $100 or $1,000 or whatever you can afford. If you wish to make a tax-exempt contribution, make your donation to the NORML Foundation. But please do your part to recognize the tremendous progress we have made over these last four decades, and to assure we continue that progress in the months and years ahead. Donate $50 or more and receive the new documentary DVD called ‘EVERGREEN: The road to marijuana legalization in Washington State’.
NORML Founder and Legal Counsel
The Congressional Research Service (CRS) released a comprehensive thirty five-page report last week examining the federal government establishing a wholesale excise tax on the production and sale of cannabis-related products.
In what is one of the most comprehensive policy and fiscal reviews to date of how cannabis can be taxed and regulated numerous areas of consideration were reviewed including enforcement, discouraging youth use, choosing the base to tax (i.e., weight, potency and price), restrictions, labeling, measurement, special tax rates, home production and medical cannabis. Members of Congress initiate these reports to CRS.
CRS’ economic analysis indicates that cannabis prices are likely to fall from today’s prohibition-influenced prices of $200-$300 an ounce to as low $5-$18 ounce. Economic modeling based on a $40 billion annual cannabis market in the United States tests a $50 per ounce federal excise tax price point (generating nearly $7 billion in federal excise taxes).
When making the logical comparison of alcohol and cannabis’ ‘external costs’ (i.e., taxation to equate with external costs of the drug use to society), researchers peg alcohol’s external costs to the nation at $30 billion annually; cannabis, at $0.5 – $1.6 billion.
NORML Executive Director Allen St. Pierre commenting on the new CRS paper: “This CRS report on the prospects of the federal government taxing and regulating cannabis is another clear indication of the political saliency and fiscal appeal of ending cannabis prohibition at the state, and increasingly at the federal level (replacing the nearly eighty-year old failed federal policy with tax-n-regulate policies that are similar to alcohol and tobacco products).
With fours states and the District of Columbia since 2012 opting for legalizing cannabis, dozens of members of Congress from both major political parties—from states with legalization and those that pine for it—are getting serious about making sure the federal government does not lose out on hundreds of millions annually in tax revenue from the ever-growing cannabis industry in the United States.”
Last week in conjunction with the well attended Marijuana Business Conference & Expo was the launch of a new business-centric webpage created to highlight the women and men of America’s nascent cannabis industry, as well as to foster needed B2B relationships and ‘best of industry’ practices among the many thousands of new cannabis-related businesses that have been founded in the last five years.
CannabisBusinessExecutive’s launch demonstrates a basic and continuing need by cannabis entrepreneurs for community and kinship in the fast growing and challenging new domestic cannabis industry, notably in the states of Alaska, Colorado, Oregon and Washington (where voters since 2012 have approved binding ballot initiatives replacing failed cannabis prohibition policies in favor of tax-n-regulate policies that look similar to existing alcohol policies).
Of note regarding CannabisBusinessExecutive’s unique content are three of it’s main features:
Additionally, for citizens interested in cannabis-related business news and investing opportunities, other excellent sources include:
For the doubting Thomas that cannabis legalization is not gaining more and more cultural and commercial cachet in America (and the world), look no further than to the major corporate cannabis branding announcement EXCLUSIVE made yesterday morning on The Today Show during the show’s prime time (7:35AM).
After several decades of Reefer Madness propaganda dominating the discussion of marijuana in the media, it should be no surprise that many Americans, especially older Americans who are not personally familiar with marijuana, believe that “getting high” is somehow a bad experience, something to be avoided by responsible citizens. It is assumed that this experience is a waste of time, or even worse, that it somehow damages the healthy individual.
Yet, I have found that marijuana smoking has been a positive experience in my life, allowing me, when I am high, to stand back half-a-step and see my life in a clearer perspective. Yes, we all know that getting high is fun: food tastes better when one is high, and music sounds better and sex is even more enjoyable. But getting high is more than just pleasurable; in the right situation, it is an enriching experience.
Specifically, if I have something I need to write, whether an article for publication or the outline for a talk I am scheduled to deliver, I find it extraordinarily helpful to isolate myself in my home office for a few hours and get stoned, allowing my mind to freely wander, making notes of any seemingly insightful thoughts that result, jotting down whatever free-associations arise, and frequently discovering issues and new ways to analyze a topic that should have been obvious to me all along, but had not come to mind until I was high.
It’s as if the marijuana high eliminates some of the barriers we otherwise construct on our imagination and our creativity. Somehow, we appear to protect ourselves from the perceived risk of thinking out of the mainstream, by closing off some creative pathways. Marijuana can reopen those pathways, and give us new understanding.
[excerpt] A new study identifying minor differences in the brain imaging of habitual marijuana consumers compared to non-users may be ideal for stimulating sensational headlines (e.g., “Regular pot smokers have shrunken brains, study says,” Los Angeles Times, November 10), but tells us little in regard to whether pot poses actual health risks.
Specifically, an MRI scan revealed less gray matter in the orbital frontal cortex of pot-smoking subjects compared to those who had never used the drug. Researchers also identified increased connectivity between certain regions of the brain in regular marijuana users compared with non-users.
So precisely what do these findings tell us in regard to pot use and health? Not much. Since the study design is not longitudinal, investigators cannot determine whether these differences are caused by subject’s cannabis use, whether these differences existed prior to subjects’ ever trying cannabis, or whether these differences persist when users’ cannabis consumption ceases.
Most importantly, investigators in this study failed to determine whether any of these differences are positively associated with any measurable adverse performance outcomes, such as cognitive performance or quality of life. It may be that these cannabis users are functioning in their daily lives in a manner that is indistinguishable from controls, in which case the imaging differences may hold little if any real-world significance. (In fact, one of the paper’s authors acknowledged, “[C]hronic users appear to be doing fine.”)
Full text of NORML’s response, “Media Leaping to Extremely Faulty Conclusions from Study on the Effects of Marijuana on the Brain,” appears online here.